Coronary disease & ACSCross-sectional study
The acute coronary syndrome (ACS) EuroPath survey series: time trends in lipid management after an acute coronary syndrome
- Repeated cross-sectional survey
- same methodology in 2024, 2022 and 2018
- 6 European countries
Authors' conclusion
The survey shows earlier lipid assessment, increased combination therapy use, and improved LDL-C goal achievement over time.
Study context
- Population
- Patients with ACS in the acute and follow-up phases, reported by cardiologists from 6 European countries530 cardiologists
- Participants
- 2,650 patients
- Exposure
- Lipid management after ACS in 2024 vs 2022 vs 2018
- Outcome
- Cardiologists' lipid management practice in the acute and follow-up phases
Main finding
As reported in the abstract
Lipid testing in acute phase
High-intensity statin monotherapy at discharge
Statin + ezetimibe
LDL-C goal attainment
Observational data: associations, not effects.
Further findings
High-intensity statin monotherapy at discharge · decreased
Statin + ezetimibe prescription · increased over time
LDL-C goal attainment · most patients not treated to LDL-C goals
LDL-C testing, acute phase
- LDL-C tested in acute phase patients, similar to 2022 and 2018
- 97%
Trained vs main group of cardiologists (subgroup)
- Trained cardiologists showed improvements in lipid testing and therapies
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Summarised from the published abstract; every number is checked against it